Bio-Plex Pro Human Diabetes 10-Plex Assay
1 x 96-well, includes conjugated magnetic beads, detection antibodies, standards, buffers, diluents, streptavidin-PE, filter plate, flat bottom plate, sealing tape, for the detection of 10 human diabetes biomarkers
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The Bio-Plex Pro™ human diabetes 10-plex immunoassay is a 1 x 96-well kit that includes coupled magnetic beads, detection antibodies, standards, assay buffer, wash buffer, sample diluent, standard diluent, detection antibody diluent, streptavidin-PE, a filter plate, flat bottom plate, and sealing tape. This multiplex assay detects:
- C-peptide
- ghrelin
- GIP
- GLP-1
- glucagon
- insulin
- leptin
- PAI-1 (total)
- resistin
- visfatin
Based on 6.5 µm magnetic beads, it is compatible with both vacuum and magnetic wash stations. Magnetic washing simplifies plate processing, provides increased throughput, and results in decreased variability and increased reproducibility.
Key Features
- Magnetic beads for simplified plate processing
- All-in-one, space-saving complete kit
- Premixed standards for generation of curves over a broad dynamic range for each target
Other Assay Formats Available
- Custom assays (mixed at the bench): available as Bio-Plex® Express assays
- Singleplex sets (each set includes a vial of coupled magnetic beads and a vial of detection bodies; requires a reagent kit (#171-304070) and a vial of standards (#171-D70001) for a complete assay)
For multiplexing capabilities with cytokine assays, refer to bulletin 5975.
Instrument Compatibility
- Bio-Plex® MAGPIX™ system
- Bio-Plex 200 system
- Bio-Plex 3D system
- Bio-Plex Pro wash station
- Bio-Plex Pro II wash station
Multiplex Analysis of Serum Biomarkers in Ovarian Cancer Patients Using Bio-Plex Suspension Array System
CA-125 tumor antigen has been the standard for monitoring response of ovarian cancer patients to therapy. However, the use of this marker for detecting ovarian cancer has been limited by both false positive and false negative results. The analysis of novel cancer biomarkers in combination with this established marker as a composite profiling tool is expected to further benefit early detection, screening, and prediction of the disease. In this study, the levels of 37 potential biomarkers were profiled. Eight markers were identified as being highly elevated in ovarian cancer samples compared to age-matched healthy controls.
